Physician profile
Alan Brockhurst
NPI 1366493892
$102,624.43
in general payments reported to CMS, 2019-2025
10 companies · $2,800 in 2025
The $2,800 reported for 2025 was more than what 85% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $12K · 2021: $20K · 2022: $19K · 2023: $48K · 2024: $600 · 2025: $2,800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Travel and Lodging: $6,185 · Consulting Fee: $4,411 · Food and Beverage: $1,781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,100.00 |
| Travel and Lodging | $6,184.66 |
| Consulting Fee | $4,411.00 |
| Food and Beverage | $1,781.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $64,288.60 | 2019-2024 | Andexxa |
| Alexion Pharmaceuticals, INC. | $23,233.49 | 2021-2022 | |
| Portola Pharmaceuticals, LLC | $12,009.94 | 2019-2020 | |
| Btg International INC. | $2,800.00 | 2025 | |
| Merck Sharp & Dohme LLC | $117.34 | 2019 | |
| Kci USA, INC. | $76.48 | 2022 | |
| Akcea Therapeutics, INC. | $36.04 | 2020 | |
| Sanofi-Aventis U.S. LLC | $33.17 | 2019 | |
| Olympus America INC. | $15.41 | 2020 | |
| Masimo Corporation | $13.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Brockhurst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.